Singapore is hosting the 5th edition of the Annual Biologistics World Asia event that brings together industry captains in the Asia-Pacific region.
This event scheduled for March 16-17th focuses on logistics and supply chain of bio-pharmaceuticals!
According to organizers, this event will bring 150+ high-profile attendees together to discuss, debate and brainstorm on the most pertinent issues affecting the biopharmaceutical logistics network.
It will be attended by decision makers who will influence the future of Asia’s healthcare logistics industry. Leverage on this year’s best marketing and sales opportunity to access the fastest growing healthcare logistics and cold chain market of the world! Your potential clients and partners are hungry for new supply chain ideas, logistic and packaging technologies and services, and they need you to make it happen.
The event is an avenue for meeting key Supply Chain, Logistics, Distribution, Procurement, Validation, & Quality stakeholders from International and Regional Biopharma, BIG Pharma, Biorepositories, CROs, Solution Providers, Academic & Research Institutes and Government & Regulatory bodies across Singapore, South Korea, Taiwan, Japan, Australia, India, Indonesia, Malaysia, and China.
This annual event is prepared from a concept that most of the biopharma companies are looking at improving the effectiveness and efficiency of their quality efforts by crafting and implementing a comprehensive program that takes the entire supply chain into account, from the materials provided by key vendors to production, packaging, disposition, and distribution.
Biologistics World Asia seeks to tackle all these challenges and introduce new perspectives in today’s fast evolving cold chain environment by bringing together key opinion leaders, rising players and market experts to discuss, debate and brainstorm on the most pertinent issues.
some key speakers include; DR. RAJ SHANKAR GHOSH Bill and Melinda Gates Foundation, CLEO KONTORAVDI Imperial College London, Andreas Weiller of Novartis, Prof. Mazen Hassanain of SaudiVax, Swapank Jana of Serum Institute of India, Rakesh Vyas of PT Sanbe Farma, and Ujwala Vilas Salvi of NUCLEON Therapeutics LLP among several others.